Therapeutic Targets in Non-Small Cell Lung Cancer: Current Progress and Future Directions

Authors

DOI:

https://doi.org/10.32932/

Keywords:

Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/genetics, Molecular Targeted Therapy, Precision Medicine, Protein Kinase Inhibitors/therapeutic use

Abstract

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases, representing the majority of cancer-related deaths worldwide. Recent advances have shifted treatment paradigms from conventional chemotherapy to precision oncology approaches, particularly molecularly targeted therapies. This review focuses on pivotal molecular drivers such as EGFR, ALK, KRAS, MET, HER2, and RET, synthesizing content from recent studies and editorial perspectives. Targeted therapies, particularly tyrosine kinase inhibitors (TKIs), have redefined patient care by improving progression-free and overall survival. However, resistance mechanisms remain a challenge, necessitating innovative strategies and combination approaches. This article integrates perspectives to provide a comprehensive overview of NSCLC target therapeutic progress and future directions.

Downloads

Download data is not yet available.

References

Mok TS, Cheng Y, Zhou X, Han JY, Katakami N, Kim HR, et al. Improved Overall Survival With Osimertinib Versus Platinum-Pemetrexed for EGFR T790M–Positive Advanced NSCLC: Results From AURA3. J Clin Oncol. 2021;39:713-22. doi:10.1200/JCO.20.03419

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. N Engl J Med. 2018;378:113-25. doi:10.1056/NEJMoa1713137

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382:41-50. doi:10.1056/NEJMoa1913662

Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, et al. Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021;39:3391-402. doi:10.1200/JCO.21.00662

Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med. 2020;383:2018-29. doi:10.1056/NEJMoa2027187

Friedlaender A, Banna GL. Diagnosis and Treatment of ALK Aberrations in NSCLC. Cancer Treat Rev. 2019;81:101371. doi:10.1016/j.ctrv.2019.101371

Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021;384:2371-81. doi:10.1056/NEJMoa2103695

Yang H, Liang SQ, Schmid RA, Peng RW. New Horizons in KRAS-Mutant Lung Cancer. Front Oncol. 2019;9:953. doi:10.3389/fonc.2019.00953

Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, et al. Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer. N Engl J Med. 2022;386:241-51. doi:10.1056/NEJMoa2112431

Perrone G, Giuliani F, Della Vittoria Scarpati G, Planchard D. Targeting the HER2 pathway in metastatic non-small cell lung cancer: current evidence and future developments. Cancers. 2021;13:4198. doi:10.3390/cancers13174198

Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, et al. Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020;383:931-43. doi:10.1056/NEJMoa2004407

Planchard D, Besse B. RET Fusion-Positive NSCLC: Treatment Advances. Lancet Oncol. 2016;17:984-93. doi:10.1016/S1470-2045(16)30146-2

Drilon A, Oxnard GR, Tan DSW, Loong HH, Johnson M, Gainor J, et al. Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer. N Engl J Med. 2020;383:813-24. doi:10.1056/NEJMoa2005653

Grenda A, Pęksa R, Jankowska-Lukomska A, Krawczyk P. Potential Role of Liquid Biopsy in Monitoring Immune-Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer Patients. Front Oncol. 2022;12:895008. doi:10.3389/fonc.2022.895008

Zhang X, Yao W, Wang H, Takebe N, Nassar AH, Karim NA, et al. Emerging insights into the use of antibody-drug conjugates for the treatment of non-small cell lung cancer. Transl Lung Cancer Res. 2022;11:2808-23. doi:10.21037/tlcr-22-838

Chen X, Lin X, Zhao J, Sharpnack MF, Wang WZ, Weigel C,et al. Combinatorial Screening Identifies Epigenetic Regulators of LKB1-Deficient Non–Small Cell Lung Cancer. Cancer Res. 2022;82:149-62. doi:10.1158/0008-5472.CAN-21-1605

Zhu H, Nguyen TB, Xu D. Combination of Poly(ADP-ribose) Polymerase and Checkpoint Kinase 1 Inhibitors Induces Synthetic Lethality in Small Cell and Non–Small Cell Lung Cancer Models. Cancer Res. 2022;82:Abstract 360.

Liu X, Nahaei M, Dastjerdi N. Artificial Intelligence in Lung Cancer: A Translational Perspective. Cancer Inform. 2022;21:11769351221119763. doi:10.1177/11769351221119763

Downloads

Published

2025-01-03

Issue

Vol. 1 No. 2 (2024)

Section

Review Article

License

Copyright (c) 2025 Author(s) (or their employer(s)) and THORAC 2024

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Most read articles by the same author(s)